Clinical Trial Update: Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial is evaluating BMX-001 as a radioprotector added to standard chemoradiation therapy for head and neck cancers and is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Cancer
• Laryngeal Cancer
• Nasopharyngeal Cancer
• Oral Cavity Cancer
• Oropharyngeal Cancer

Drugs mentioned

• BMX-001

Snippet

Sponsor: NRG Oncology | Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Status: RECRUITING